Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Longeveron names Bailey as Vice President of Business Operations » 08:38
09/15/22
09/15
08:38
09/15/22
08:38
LGVN

Longeveron

$4.90 /

+0.03 (+0.62%)

, REGN

Regeneron

$697.48 /

-5 (-0.71%)

Longeveron (LGVN)…

Longeveron (LGVN) announced it has named Jerome Bailey as the company's new vice president of business operations. He joins the company from Checkmate Pharmaceuticals, acquired by Regeneron (REGN), where he served as senior director of program management.

ShowHide Related Items >><<
REGN Regeneron
$697.48 /

-5 (-0.71%)

LGVN Longeveron
$4.90 /

+0.03 (+0.62%)

LGVN Longeveron
$4.90 /

+0.03 (+0.62%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
REGN Regeneron
$697.48 /

-5 (-0.71%)

09/13/22 Piper Sandler
Regeneron price target raised to $775 from $692 at Piper Sandler
09/12/22 Piper Sandler
Regeneron data at ESMO showcases 'power' of oncology pipeline, says Piper
09/12/22 Guggenheim
Regeneron price target raised to $925 from $740 at Guggenheim
09/12/22 Wells Fargo
Regeneron price target raised to $800 from $735 at Wells Fargo
REGN Regeneron
$697.48 /

-5 (-0.71%)

LGVN Longeveron
$4.90 /

+0.03 (+0.62%)

REGN Regeneron
$697.48 /

-5 (-0.71%)

LGVN Longeveron
$4.90 /

+0.03 (+0.62%)

REGN Regeneron
$697.48 /

-5 (-0.71%)

Over a month ago
Hot Stocks
Longeveron announces FDA granted Fast Track Designation to Lomecel-B » 08:32
08/31/22
08/31
08:32
08/31/22
08:32
LGVN

Longeveron

$5.18 /

-0.1 (-1.89%)

Longeveron announced the…

Longeveron announced the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation to Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome, HLHS, a rare and life-threatening congenital heart defect affecting approximately 1,000 infants per year. Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell product, is currently in a Phase 2a trial for HLHS. "Fast Track Designation represents a significant milestone in our efforts to develop Lomecel-B as a treatment for infants with HLHS," said Chris Min, M.D., Ph.D., Longeveron's Interim Chief Executive Officer and Chief Medical Officer. "Fast Track Designation underscores the urgent need in HLHS, and we look forward to continuing to work closely with the FDA to bring this potential new therapy to infants as expeditiously as possible."

ShowHide Related Items >><<
LGVN Longeveron
$5.18 /

-0.1 (-1.89%)

LGVN Longeveron
$5.18 /

-0.1 (-1.89%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
LGVN Longeveron
$5.18 /

-0.1 (-1.89%)

LGVN Longeveron
$5.18 /

-0.1 (-1.89%)

Hot Stocks
Longeveron receives intent to grant notice from European Patent Office » 08:09
08/25/22
08/25
08:09
08/25/22
08:09
LGVN

Longeveron

$5.23 /

+0.03 (+0.58%)

Longeveron announced that…

Longeveron announced that the European Patent Office has issued a notice of its intent to grant the Company a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic mesenchymal cell therapies, also known as medicinal signaling cells. The cells are administered to patients with cardiovascular disease through the monitoring of a protein, Vascular Endothelial Growth Factor, which is a signal protein produced by many cells that stimulates the formation of blood vessels. The patent is titled "Methods for Monitoring Efficacy of Allogeneic Mesenchymal Stem Cell Therapy in a Subject." Longeveron's lead investigational product is Lomecel-B, a cell therapy product derived from MSCs. Longeveron is also conducting a trial of Lomecel-B in patients with Alzheimer's Disease in the US and for aging frailty in Japan. Now that the European Patent Office has issued an Intention to Grant, Longeveron will await grant of the patent and then begin the process of registering the patent in a number of nation members of the European Patent Organization. In those jurisdictions where the patent is registered, the patent is expected to expire in November of 2035.

ShowHide Related Items >><<
LGVN Longeveron
$5.23 /

+0.03 (+0.58%)

LGVN Longeveron
$5.23 /

+0.03 (+0.58%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
LGVN Longeveron
$5.23 /

+0.03 (+0.58%)

LGVN Longeveron
$5.23 /

+0.03 (+0.58%)

Hot Stocks
Longeveron expects cash to cover requirements into 1H24 » 08:04
08/12/22
08/12
08:04
08/12/22
08:04
LGVN

Longeveron

$5.96 /

-0.17 (-2.77%)

Cash and short-term…

Cash and short-term investments was $27.0 million and $35.0 million as of June 30, 2022, and December 31, 2021, respectively.

ShowHide Related Items >><<
LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

Earnings
Longeveron reports Q2 EPS (27c), consensus (23c) » 08:03
08/12/22
08/12
08:03
08/12/22
08:03
LGVN

Longeveron

$5.96 /

-0.17 (-2.77%)

Reports Q2 revenue…

Reports Q2 revenue $466,000 vs. $489,000 last year. "Longeveron has made steady progress advancing Lomecel-B, our lead medicinal signaling cell (MSC) therapy product, through clinical trials for four different indications," said Chris Min, M.D., Ph.D., Interim Chief Executive Officer and Chief Medical Officer. "Today I am proud to announce multiple updates on all of our projects. First, we have enrolled 50% of our planned patient population of 48 in our Phase 2a trial of Lomecel-B in patients with mild Alzheimer's Disease. Furthermore, a pre-planned total of 89 patients have been consented to undergo eligibility screening, and we expect to fully enroll the study on schedule. In addition, on August 8, 2022, the Japanese Pharmaceuticals and Medical Devices Agency accepted an amendment to our Japanese Aging Frailty Trial. We reevaluated our Aging Frailty strategy in Japan given the large unmet need there, and the supportive regulatory framework including the pathway recognizing the therapeutic potential of cell therapies through the Act on the Safety of Regenerative Medicine. ASRM approval, if granted, could allow Longeveron to provide Lomecel-B in Japan at selected sites, permitting us to enter the market in that country on an accelerated basis. We have increased confidence in the near-term, value-driving opportunity in Japan. We also announced that we met the primary safety endpoint in the randomized phase of our Phase 1/2 'HERA' Aging Frailty trial. In that study, Lomecel-B does not appear to interfere with the potency of vaccines such as HD Fluzone in the adult population with aging frailty. In the remainder of 2022 through early 2023, we expect to publish manuscripts for the ELPIS 1 trial and for the previously completed Phase 2b study in Adult Frailty in quality peer-reviewed journals, enroll the first Japanese patient with aging frailty in our Phase 2 study in that country, and complete enrollment of our Phase 2a trial in Alzheimer's Disease."

ShowHide Related Items >><<
LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

Over a quarter ago
Hot Stocks
Longeveron sees cash, equivalents funding operations into 1H24  08:07
05/13/22
05/13
08:07
05/13/22
08:07
LGVN

Longeveron

$7.21 /

+0.28 (+4.04%)

 
ShowHide Related Items >><<
LGVN Longeveron
$7.21 /

+0.28 (+4.04%)

LGVN Longeveron
$7.21 /

+0.28 (+4.04%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
LGVN Longeveron
$7.21 /

+0.28 (+4.04%)

LGVN Longeveron
$7.21 /

+0.28 (+4.04%)

Earnings
Longeveron reports Q1 EPS (17c) vs. (18c) last year » 08:07
05/13/22
05/13
08:07
05/13/22
08:07
LGVN

Longeveron

$7.21 /

+0.28 (+4.04%)

Reports Q1 revenue…

Reports Q1 revenue $370,000 vs. $376,000 last year.

ShowHide Related Items >><<
LGVN Longeveron
$7.21 /

+0.28 (+4.04%)

LGVN Longeveron
$7.21 /

+0.28 (+4.04%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
LGVN Longeveron
$7.21 /

+0.28 (+4.04%)

LGVN Longeveron
$7.21 /

+0.28 (+4.04%)

Hot Stocks
Longeveron CEO Geoff Green to resign » 16:23
05/09/22
05/09
16:23
05/09/22
16:23
LGVN

Longeveron

$7.92 /

-0.475 (-5.66%)

Longeveron announced the…

Longeveron announced the resignation of CEO Geoff Green, who is leaving the company effective June 1 to pursue new opportunities. Longeveron's board has approved the appointment of current Chief Medical Officer, K. Chris Min, M.D., Ph.D., as interim CEO, to succeed Green. The board has formed a search committee and retained an executive search firm to assist in identifying a permanent CEO. The company currently intends to enter into a consulting agreement with Green to further ensure a smooth transition.

ShowHide Related Items >><<
LGVN Longeveron
$7.92 /

-0.475 (-5.66%)

LGVN Longeveron
$7.92 /

-0.475 (-5.66%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
LGVN Longeveron
$7.92 /

-0.475 (-5.66%)

LGVN Longeveron
$7.92 /

-0.475 (-5.66%)

Hot Stocks
Longeveron enters into CRADA with US Department of VA » 08:07
04/13/22
04/13
08:07
04/13/22
08:07
LGVN

Longeveron

$9.98 /

+1.08 (+12.13%)

Longeveron announced a…

Longeveron announced a Cooperative Research and Development Agreement, CRADA, with the United States Department of Veterans Affairs, VA, for the addition of a Miami VA clinical site to its ongoing Phase 2 Alzheimer's Disease, AD, trial. As recently reported in a peer reviewed article in Alzheimer's & Dementia, The Journal of the Alzheimer's Association, Longeveron's Phase 1 trial met its primary endpoint, demonstrating that its drug Lomecel-B was well tolerated in Alzheimer's patient. "After meeting the rigorous requirements of the VA, we are pleased to announce the addition of this particular Miami VA site to our ongoing trial," said Geoff Green, Chief Executive Officer at Longeveron. "This continued collaboration between Longeveron and the Miami VA reflects our ongoing efforts to develop a safe and effective cell-based therapy for this devastating disease in the vital setting of the VA health system." This marks the third separate CRADA agreement between the VA and Longeveron, including an Aging Frailty study and an ongoing study on Covid-19.

ShowHide Related Items >><<
LGVN Longeveron
$9.98 /

+1.08 (+12.13%)

LGVN Longeveron
$9.98 /

+1.08 (+12.13%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
LGVN Longeveron
$9.98 /

+1.08 (+12.13%)

LGVN Longeveron
$9.98 /

+1.08 (+12.13%)

On The Fly
Fly Intel: After-Hours Movers » 18:14
04/05/22
04/05
18:14
04/05/22
18:14
ARRY

Array Technologies

$10.57 /

-1.355 (-11.37%)

, GOGO

Gogo

$19.19 /

-0.545 (-2.76%)

, AFYA

Afya

$13.88 /

-0.505 (-3.51%)

, IOVA

Iovance Biotherapeutics

$16.58 /

-0.725 (-4.19%)

, RIVN

Rivian Automotive

$42.17 /

-4.33 (-9.31%)

, SGH

SGH

$23.20 /

-1.275 (-5.21%)

, LGVN

Longeveron

$11.60 /

-1.205 (-9.41%)

, JBLU

JetBlue

$13.65 /

-1.02 (-6.95%)

, SAVE

Spirit Airlines

$26.82 /

+4.84 (+22.02%)

Check out this evening's…

ShowHide Related Items >><<
SGH SGH
$23.20 /

-1.275 (-5.21%)

SAVE Spirit Airlines
$26.82 /

+4.84 (+22.02%)

RIVN Rivian Automotive
$42.17 /

-4.33 (-9.31%)

LGVN Longeveron
$11.60 /

-1.205 (-9.41%)

JBLU JetBlue
$13.65 /

-1.02 (-6.95%)

IOVA Iovance Biotherapeutics
$16.58 /

-0.725 (-4.19%)

GOGO Gogo
$19.19 /

-0.545 (-2.76%)

ARRY Array Technologies
$10.57 /

-1.355 (-11.37%)

AFYA Afya
$13.88 /

-0.505 (-3.51%)

ARRY Array Technologies
$10.57 /

-1.355 (-11.37%)

01/31/22 Goldman Sachs
Array Technologies price target lowered to $20 from $24 at Goldman Sachs
01/24/22 Truist
Array Technologies price target lowered to $14 from $27 at Truist
01/20/22 JPMorgan
Array Technologies price target lowered to $32 from $38 at JPMorgan
01/18/22 Guggenheim
Array Technologies resumed with a Neutral at Guggenheim
GOGO Gogo
$19.19 /

-0.545 (-2.76%)

03/24/22 William Blair
Gogo shares headed to low $30s by 2024, says William Blair
03/03/22 Roth Capital
Gogo price target raised to $21 from $20.50 at Roth Capital
01/07/22 William Blair
William Blair sees Gogo shares trending to low $30s by 2024
12/20/21 JPMorgan
JPMorgan 'more favorable today' on Gogo than in some time
AFYA Afya
$13.88 /

-0.505 (-3.51%)

02/14/22 Goldman Sachs
Afya price target lowered to $19 from $29 at Goldman Sachs
07/21/21
Fly Intel: Top five analyst downgrades
07/21/21 Morgan Stanley
Afya downgraded to Equal Weight from Overweight at Morgan Stanley
04/15/21 UBS
UBS upgrades Afya to Buy on 'underappreciated resiliency'
IOVA Iovance Biotherapeutics
$16.58 /

-0.725 (-4.19%)

02/28/22 Truist
Iovance Biotherapeutics price target lowered to $32 from $45 at Truist
02/25/22 Chardan
Iovance Biotherapeutics price target lowered to $45 from $50 at Chardan
02/25/22 Baird
Iovance Biotherapeutics price target lowered to $30 from $35 at Baird
01/28/22 Stifel
Iovance Biotherapeutics upgraded to Buy from Hold at Stifel
RIVN Rivian Automotive
$42.17 /

-4.33 (-9.31%)

03/24/22 Mizuho
Rivian Automotive price target lowered to $95 from $100 at Mizuho
03/11/22 RBC Capital
Rivian Automotive price target lowered to $100 from $116 at RBC Capital
03/11/22 Wedbush
Rivian Automotive price target lowered to $60 from $130 at Wedbush
03/11/22 Baird
Rivian Automotive price target lowered to $84 from $100 at Baird
SGH SGH
$23.20 /

-1.275 (-5.21%)

02/08/22 Barclays
SGH price target lowered to $35 from $82 at Barclays
01/10/22 Stifel
Stifel sees 'material boost' to SGH consensus earnings from PADIS extension
01/05/22 Stifel
Stifel views SGH stock reaction after earnings report as 'unduly severe'
01/05/22 Deutsche Bank
SGH price target raised to $80 from $70 at Deutsche Bank
LGVN Longeveron
$11.60 /

-1.205 (-9.41%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
JBLU JetBlue
$13.65 /

-1.02 (-6.95%)

02/15/22 Wolfe Research
Wolfe upgrades three, downgrades one in U.S. Airlines as new analyst takes over
02/15/22 Wolfe Research
JetBlue assumed at Peer Perform from Underperform at Wolfe Research
01/14/22 Barclays
JetBlue price target lowered to $17 from $20 at Barclays
01/03/22 MKM Partners
JetBlue downgraded to Sell from Neutral at MKM Partners
SAVE Spirit Airlines
$26.82 /

+4.84 (+22.02%)

02/09/22 JPMorgan
Spirit Airlines risk/reward 'very attractive,' says JPMorgan
02/09/22 Deutsche Bank
Spirit Airlines price target raised to $38 from $30 at Deutsche Bank
01/14/22 Barclays
Spirit Airlines price target lowered to $38 from $46 at Barclays
SGH SGH
$23.20 /

-1.275 (-5.21%)

SAVE Spirit Airlines
$26.82 /

+4.84 (+22.02%)

RIVN Rivian Automotive
$42.17 /

-4.33 (-9.31%)

LGVN Longeveron
$11.60 /

-1.205 (-9.41%)

JBLU JetBlue
$13.65 /

-1.02 (-6.95%)

IOVA Iovance Biotherapeutics
$16.58 /

-0.725 (-4.19%)

GOGO Gogo
$19.19 /

-0.545 (-2.76%)

ARRY Array Technologies
$10.57 /

-1.355 (-11.37%)

AFYA Afya
$13.88 /

-0.505 (-3.51%)

  • 10
    Nov
SAVE Spirit Airlines
$26.82 /

+4.84 (+22.02%)

RIVN Rivian Automotive
$42.17 /

-4.33 (-9.31%)

JBLU JetBlue
$13.65 /

-1.02 (-6.95%)

ARRY Array Technologies
$10.57 /

-1.355 (-11.37%)

SGH SGH
$23.20 /

-1.275 (-5.21%)

SAVE Spirit Airlines
$26.82 /

+4.84 (+22.02%)

RIVN Rivian Automotive
$42.17 /

-4.33 (-9.31%)

JBLU JetBlue
$13.65 /

-1.02 (-6.95%)

IOVA Iovance Biotherapeutics
$16.58 /

-0.725 (-4.19%)

GOGO Gogo
$19.19 /

-0.545 (-2.76%)

ARRY Array Technologies
$10.57 /

-1.355 (-11.37%)

SGH SGH
$23.20 /

-1.275 (-5.21%)

SAVE Spirit Airlines
$26.82 /

+4.84 (+22.02%)

RIVN Rivian Automotive
$42.17 /

-4.33 (-9.31%)

JBLU JetBlue
$13.65 /

-1.02 (-6.95%)

GOGO Gogo
$19.19 /

-0.545 (-2.76%)

ARRY Array Technologies
$10.57 /

-1.355 (-11.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.